Grant Life Sciences, Inc.
DTL to develop, commercialize Grant's cervical cancer-diagnostic technology
Published in Law and Health Weekly, May 13th, 2006
Under the MOU, Grant will receive an upfront licensing fee of $250,000. In addition, the MOU calls for DTL to conduct all development at its own cost, including clinical trials, associated with the commercialization of the products developed from Grant's cervical cancer-diagnostic technology. Upon commercialization, DTL will pay Grant an ongoing royalty on sales of the products developed, according to the...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Law and Health Weekly
More Articles from Law and Health Weekly
- Cell Therapeutics, Inc.
Cell Therapeutics, Inc. granted U.S. patent for antitubulin agents with anti-cancer activity - Columbia University, New York
Cyclophilin A and TRIM5 alpha independently regulate HIV infectivity - DUA Pharmaceuticals, Inc.
DUSA Pharmaceuticals and New England Compounding Center announce favorable settlement - Federal University of Minas Gerais
Botulinum A toxin injected into gastric wall was safe treatment option for class III obesity - Healthcare Coverage
Centers for Medicare and Medicaid Services (CMS) advises Niaspan is now Part D-eligible - Healthcare Coverage
Nine new health plans enter the Texas Medicare market, according to HealthLeaders-InterStudy - More from this issue of Law and Health Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
